Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H10N2.ClH |
| Molecular Weight | 230.693 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1=C2C=CC=CC2=NC3=CC=CC=C13
InChI
InChIKey=FTGPOQQGJVJDCT-UHFFFAOYSA-N
InChI=1S/C13H10N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1-8H,(H2,14,15);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C13H10N2 |
| Molecular Weight | 194.2319 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.pnas.org/content/74/1/188.full.pdfCurator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23841224
Sources: http://www.pnas.org/content/74/1/188.full.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23841224
Aminacrine has long been known to be a potent frameshift mutagen in viruses and bacteria. It is one in a general class of aminoacridine dyes that bind to DNA and possess mutagenic activity. Aminacrine is used clinically as a topical antiseptic. A part from therapeutic use, aminacrine is also introduced as a matrix for negative mode matrix-assisted laser desorption/ionization (MALDI).
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
14 mg 2 times / day multiple, vaginal Recommended Dose: 14 mg, 2 times / day Route: vaginal Route: multiple Dose: 14 mg, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Vulvovaginal discomfort... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Vulvovaginal discomfort | 2 patients | 14 mg 2 times / day multiple, vaginal Recommended Dose: 14 mg, 2 times / day Route: vaginal Route: multiple Dose: 14 mg, 2 times / day Sources: |
unhealthy, adult |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of Leishmania infantum. | 2010-10 |
|
| Mononuclear Fe(II)-N4Py complexes in oxidative DNA cleavage: structure, activity and mechanism. | 2010-09-14 |
|
| MALDI-TOF/MS analysis of archaebacterial lipids in lyophilized membranes dry-mixed with 9-aminoacridine. | 2010-09 |
|
| Lipidomic analysis of porcine olfactory epithelial membranes and cilia. | 2010-07 |
|
| Mutagenic and antimutagenic effects of hexane extract of some Astragalus species grown in the eastern Anatolia region of Turkey. | 2010-07 |
|
| Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions. | 2010-06-30 |
|
| Significant sensitivity improvements by matrix optimization: a MALDI-TOF mass spectrometric study of lipids from hen egg yolk. | 2010-06 |
|
| Selective desorption/ionization of sulfatides by MALDI-MS facilitated using 9-aminoacridine as matrix. | 2010-06 |
|
| The surface charge density of plant cell membranes (sigma): an attempt to resolve conflicting values for intrinsic sigma. | 2010-05 |
|
| Host hindrance to HIV-1 replication in monocytes and macrophages. | 2010-04-07 |
|
| The intact muscle lipid composition of bulls: an investigation by MALDI-TOF MS and 31P NMR. | 2010-02 |
|
| Genotoxicity and antigenotoxicity evaluation of non-photoactivated hypericin. | 2010-01 |
|
| Investigation on the Interactions of NiCR and NiCR-2H with DNA. | 2010 |
|
| Alveolar osteitis: a comprehensive review of concepts and controversies. | 2010 |
|
| Phosphatidylcholines and -ethanolamines can be easily mistaken in phospholipid mixtures: a negative ion MALDI-TOF MS study with 9-aminoacridine as matrix and egg yolk as selected example. | 2009-12 |
|
| Identification of chemical compounds that induce HIF-1alpha activity. | 2009-11 |
|
| Binding of TCA to the prion protein: mechanism, implication for therapy, and application as probe for complex formation of bio-macromolecules. | 2009-10 |
|
| A kinetic and structural investigation of DNA-based asymmetric catalysis using first-generation ligands. | 2009-09-21 |
|
| 9-Aminoacridine inhibition of HIV-1 Tat dependent transcription. | 2009-07-24 |
|
| In situ primary metabolites localization on a rat brain section by chemical mass spectrometry imaging. | 2009-07-01 |
|
| Biological safety of LipoFullerene composed of squalane and fullerene-C60 upon mutagenesis, photocytotoxicity, and permeability into the human skin tissue. | 2009-06 |
|
| Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. | 2009-04-01 |
|
| Biological safety of liposome-fullerene consisting of hydrogenated lecithin, glycine soja sterols, and fullerene-C60 upon photocytotoxicity and bacterial reverse mutagenicity. | 2009-04 |
|
| 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. | 2009-02-26 |
|
| Blockade of NMDA receptor channels by 9-aminoacridine and its derivatives. | 2009-02-13 |
|
| Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials. | 2009-01-22 |
|
| Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. | 2009-01-14 |
|
| Matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis of cellular glycerophospholipids enabled by multiplexed solvent dependent analyte-matrix interactions. | 2008-10-01 |
|
| New palladium(II) and platinum(II) complexes with 9-aminoacridine: structures, luminiscence, theoretical calculations, and antitumor activity. | 2008-08-04 |
|
| Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. | 2008-05-15 |
|
| Negative ion mode matrix-assisted laser desorption/ionisation time-of-flight mass spectrometric analysis of oligosaccharides using halide adducts and 9-aminoacridine matrix. | 2008-04 |
|
| Effect of spermine conjugation on the interaction of acridine with alternating purine-pyrimidine oligodeoxyribonucleotides studied by CD, fluorescence and absorption spectroscopies. | 2008-04 |
|
| Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. | 2008-03-18 |
|
| Ultrasonic trapping of microparticles in suspension and reaction monitoring using Raman microspectroscopy. | 2007-10-15 |
|
| Modulation of the genotoxicity of bleomycin by amines through noncovalent DNA interactions and alteration of physiological conditions in yeast. | 2007-10-01 |
|
| The electrochemical behavior and direct determination of tyrosine at a glassy carbon electrode modified with poly (9-aminoacridine). | 2007-10 |
|
| A role of the 9-aminoacridines and their conjugates in a life science. | 2007-10 |
|
| Frameshift mutations produced by 9-aminoacridine in wild-type, uvrA and recA strains of Escherichia coli; specificity within a hotspot. | 2007-09 |
|
| In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase. | 2007-08-07 |
|
| Preparation of magnetite nanocrystals with surface reactive moieties by one-pot reaction. | 2007-07-15 |
|
| Unexpected reactivity of the 9-aminoacridine chromophore in guanidylation reactions. | 2007-07-06 |
|
| Molecular recognition of DNA by rigid [N]-polynorbornane-derived bifunctional intercalators: synthesis and evaluation of their binding properties. | 2007-05-17 |
|
| Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compounds. | 2007-04 |
|
| A binary matrix for background suppression in MALDI-MS of small molecules. | 2007-03 |
|
| A real-time fluorescence assay for measuring N-dealkylation. | 2007-01 |
|
| Complexes of Pd(II) and Pt(II) with 9-aminoacridine: reactions with DNA and study of their antiproliferative activity. | 2007 |
|
| Analysis of low molecular weight acids by negative mode matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | 2007 |
|
| Quantitative detection of metabolites using matrix-assisted laser desorption/ionization mass spectrometry with 9-aminoacridine as the matrix. | 2007 |
|
| Imaging Matrix Assisted Laser Desorption Ionization Mass Spectrometry: a technique to map plant metabolites within tissues at high spatial resolution. | 2007 |
|
| Acridin-9-yl exchange: a proposal for the action of some 9-aminoacridine drugs. | 2006 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9132982
Vaginal suppositories containing 1.05 g of sulfanilamide, 14 mg of aminacrine hydrochloride, and 140 mg of allantoin (AVC suppositories) were given twice a day for 7 days.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7678123
S. typhimurium cells were treated with aminacrine at concentration of 2-250 ug/ml and incubated during 60 min.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:58:41 GMT 2025
by
admin
on
Mon Mar 31 17:58:41 GMT 2025
|
| Record UNII |
OR5RM3Q5QL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 310.531
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
||
|
EPA PESTICIDE CODE |
55503
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB00450MIG
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
8643
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
7571
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
134-50-9
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
205-145-5
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
m1672
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
81949
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
C77024
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
100000085173
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
CHEMBL43184
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
OR5RM3Q5QL
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
DTXSID8030473
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
74837
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY | |||
|
4505
Created by
admin on Mon Mar 31 17:58:41 GMT 2025 , Edited by admin on Mon Mar 31 17:58:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |